Recent Posts

February 10th, 2012

Boceprevir – PI Interaction: A “Dear Doctor” Letter We Didn’t Want To Get

By now I’m sure that most of you ID folks out there have received the following letter from Merck, the makers of boceprevir:

URGENT — IMPORTANT DRUG WARNING: VICTRELIS (BOCEPREVIR)

The purpose of this communication is to inform you of recent pharmacokinetic study results evaluating drug interactions between VICTRELIS, an oral chronic hepatitis C virus (HCV) NS3/4A protease inhibitor, and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors … VICTRELIS reduced mean trough concentrations of ritonavir-boosted atazanavir, lopinavir, and darunavir by 49%, 43%, and 59%, respectively. Merck does not recommend the coadministration of VICTRELIS and ritonavir-boosted HIV protease inhibitors.

Boceprevir levels were also substantially lowered by lopinavir/r and darunavir/r.

Yes, we already knew that the telaprevir-boosted PI interactions were tricky. It’s basically atazanavir/ritonavir, no other options.

(Outside of the boosted PIs, you can use raltegravir or efavirenz with telaprevir, but the latter requires, 1125 mg three times/day, upping the cost by 50%. Gasp.)

The reason this “Dear Doctor” letter was so disappointing was that boceprevir was supposed to be easier in this regard. In this study presented at IDSA of peg/ribavirin + boceprevir for co-infected patients, all boosted PIs were allowed, only NNRTIs excluded. But that study was small (n=64), and in hindsight perhaps the slower-than-expected HCV RNA reduction had a pharmacokinetic explanation.

For now, the bottom line is that there really is no optimal HCV protease inhibitor for HIV/HCV co-infected patients, especially for those on a boosted PI.

And why careful assessment of those with HIV/HCV is critical, as many patients are stable enough to wait for the next wave of HCV drugs.

February 7th, 2012

Chronic Fatigue: Is There Hope After XMRV?

I’ve been following the chronic fatigue/XMRV story from the start, which was compelling for several reasons, including:

  1. A potential cause was identified of a very debilitating, mysterious illness.
  2. Lots of very smart ID people (including some of my colleagues) studied it.
  3. Media coverage, notably from the Wall Street Journal and the New York Times, was particularly skillful.

In that last vein, the Times today has a fascinating summary of the current situation for this once promising link.

In a word, the link is kaput

After numerous investigators were unable to duplicate the original results, Science issued an “Expression of Concern” about the paper they had published in 2009. Then in late December, that paper was fully retracted by the Editor of the journal, as was a key supporting paper — really the only supporting paper — that had been published in the Proceedings of the National Academy of Sciences. 

Could things get any worse? Of course. Here’s what’s come of the lead investigator in the original Science paper:

Dr. Mikovits left her position as research director at the [Whittemore Peterson Institute] in a dispute over management practices and control over research materials. The institute sued her, accusing her of stealing notebooks and other proprietary items. Dr. Mikovits was arrested in Southern California, where she lives, and jailed for several days, charged with being a fugitive from justice.

Yikes.

But even with all these clouds, there’s an  important silver lining to all this news nicely articulated by a noted virologist:

“The disease had languished in the background at N.I.H. and C.D.C., and other scientists had not been paying much attention to it,” said John Coffin, a professor of molecular biology at Tufts University. “This has brought it back into attention.”

I couldn’t agree more. And with that greater attention, perhaps we’ll see some discoveries that really help people.

February 3rd, 2012

More on Low (but Detectable) Viral Loads — Is Knowing This Useful?

I have a very smart, very experienced colleague — clue, his initials are CC, and he doesn’t pitch for the Yankees — who continues to use bDNA testing for HIV viral load monitoring. You know, the assay with a lower limit of detection of 75 copies.

He knows that bDNA is less sensitive than PCR.

He knows that it’s more expensive than PCR.

He even knows (I think) that it’s less accurate than PCR.

So why does he use it?  Because he detests the added anxiety and aggravation that these periodic low-level results — usually 20-200 copies, or “<20 but target detected” — give his patients. More importantly, he’s not convinced it provides him with any useful information.

I certainly get that. And suspect he’s not alone in using this (ancient) test, which is probably best known for a study that put viral load testing on the map way back when.

But I can’t bring myself to use an inferior and more expensive test, so I’ve switched whole-hog to PCR. As a result, I’ve been forced to learn a whole new speech to give to patients when these results come back. It usually goes something like this:

Gerald [not his real name], the result came back at 43…  Yes, this is detectable, but remember our old test only went down to 50, so in fact this is a great result — keep up the good work … No, I’m not worried … If you’re worried we can repeat it, but I can assure you I won’t recommend changing meds even if it comes back the same … Yes I’m sure … You’re welcome.

Now it’s been a few years since we’ve had these tests, and several studies (like this one) thus far didn’t even suggest any significance to these low-level detectable results.

Until now.

Over in Journal Watch AIDS Clinical Care, Helmut Albrecht summarizes a recent study that compares the likelihood of virologic rebound in 1247 patients who had viral loads measured by the RealTime PCR assay. Three groups were defined:  those with results between 40-49 (Group A), < 40 but detectable (Group B), and truly undetectable (Group C):

The proportion of patients who experienced viral rebound to >50 copies/mL was 34.2% for group A, 11.3% for group B, and 4.0% for group C. The proportion with rebound to >400 copies/mL was 13.0%, 3.8%, and 1.2%, respectively. These associations were independent of adherence levels.

Based on these data, it does seem that the lower the viral load, the better — but wait!

Is there more resistance among those who rebounded? No.

Could this just be a proxy for duration of virologic suppression?  Highly likely.

Is there a different clinical outcome among those who rebounded? Not commented on, but highly doubtful.

Is there any evidence that our management should be changed based on these fascinating results, however biologically plausible they may be? Emphatically NO.  Or at least, not yet. Good summary of these issues in Raj Gandhi’s accompanying editorial.

Which is why CC can continue to use the bDNA — it’s defensible — and while I’ll press on with PCR and all it’s telling us about low-level viremia. Knowledge is power, after all.

I’m just not sure what to do with it yet.

January 29th, 2012

Pre-Super Sunday Scombroids

Some quick ID/HIV links while we await big guys playing the big game with a big (or at least bigger) ball.

  • Did you see how this doctor cheated Medicaid out of more than $700,000 by prescribing HIV meds to people who didn’t have HIV? Not surprisingly, he’s going to jail. Proof that if there’s money behind a program — no matter how beneficial — someone will figure out a way to scam it.
  • Not only is there barely any winter this year, but there’s hardly any influenza. Not a single state is reporting widespread activity. But Google Flu doesn’t think it’s quite so remarkable, especially compared to last year where flu season peaked in mid-late February.
  • What we’re not getting in flu, however, we’re definitely getting in norovirus activity, at least here in Boston. Last week someone in our office turned the color of a bedsheet, then disappeared home, only to returned a few days later weak, tired and 10 pounds lighter. And she didn’t even get to go on a cruise, though maybe that’s a good thing this year.
  • Good brief piece in the Times about men of a certain age getting HIV. As the author awaits the results of his test, he writes “I was feeling an incipient sense of . . . failure.”  That part particularly rang true, based on my clinical experience — these men lived through the horrible early years of the epidemic, and they feel like failures to get HIV now, after all these years. Lots of self blame.
  • How about we all pick up one of these beauties for our hospitals before flu season kicks in? The Mold and Germ Destroying Air Purifier “eliminates up to 100% of airborne bacteria, mold, viruses, pet dander, dust mites, and pollen without making a sound or using a filter.” I guess the key is that “up to …” phrase. (Note to catalogue copy writers: doctors never use the word “germs” unless talking to non-medical people.)

For reference, today’s title was brought to you by the makers of the ABIM Recertification Exam, who truly have a thing for fish poisonings.

    January 22nd, 2012

    Generic Lamivudine Has Arrived

    An e-mail from a patient last week:

    Just got refills. Epivir is now generic???  Refill is simply labeled Lamivudine Tablets by Aurobindo Pharma USA, Inc …but made in India.  Should I be concerned about that???
    John

    I told John (not his real name) not to be concerned — he is merely substituting the generic for the branded version, not switching from a fixed-dose combination or from a different drug (that drug being emtricitabine, or FTC).

    With all the hoo-ha about generic atorvastatin, this one is much more under the radar. And the process to approval has not been smooth, as I wrote about here and here.

    But generic lamivudine for HIV treatment is a watershed moment nonetheless, since it’s really the first time there’s a generic antiretroviral that we might actually consider prescribing. (Zidovudine and didanosine have been generic for years.)

    It will be fascinating to see how this plays out, both here in the US and in other developed countries.

    January 21st, 2012

    More Medical Testing! No, Less! You Decide

    Fascinating Yin-Yang this week on the issue of medical testing. Want more? Want less?

    First, this remarkable piece on retail medical labs, including a description of a company called ANY LAB TEST NOW:

    Labs where folks can just walk in and order tests on themselves are popping up in retail centers across the country… At Any Lab Test Now, co-owner Anthony Richey pulls out a long sheet of paper with all the different tests his lab offers. There’s everything from an HIV screening to a “fatigue” panel. It looks like a sushi menu. “You say, ‘Well I want to check my diabetes, I want to get a hemoglobin A1C, and maybe I’ll check my lipid panel. And I’m a male over 40 so I’ll get my PSA checked,’ ” Richey says.

    On the company’s web site, there are plenty of smiling, healthy people, plus these appealing claims:  “No Doctor’s order needed … No appointment necessary … No insurance needed …  Most results available in 24-48 hours.”

    No doubt this is excellent customer service. But care to guess what that “Fatigue Panel” will set you back? That will be $499, thank you very much. But maybe they offer Gift Cards, that should help.

    And if anything comes back abnormal?

    If your results are ‘abnormal’ or ‘out-of-range’ from the normal, please contact your physician.

    Joy.

    It’s a poorly appreciated fact that the lower the likelihood of a disease being present, the greater the chance of a false-positive result.

    Which is why no sensible physician would order all the components in the “Fatigue Panel” — which of course includes Lyme and EBV testing — without first taking a thorough history to determine if these diseases are even worth considering.

    Meanwhile, over in the Annals of Internal Medicine, a group from the American College of Physicians this week argues for less testing:

    The overuse of some screening and diagnostic tests is an important component of unnecessary health care costs… Efforts to control expenditures should focus not only on benefits, harms, and costs but on the value of diagnostic tests—meaning an assessment of whether a test provides health benefits that are worth its costs or harms.

    What follows is an entirely sensible view of medical testing, with certain problematic, “low-value” tests called out for being wasteful — including the Lyme test mentioned in that “Fatigue Panel.”

    And those false-positive tests, which retail labs must be generating by the crateload every day?

    False-positive results are of concern because they often lead to further testing, which may be expensive and potentially harmful. They may also create anxiety for the patient and may lead to inappropriate treatment.

    Which brings us back to the primary motivation of ANY LAB TEST NOW, which must be obvious by now:

    “From a marketing standpoint it’s a good position to be in where you create a service, create a demand,” says Rodney Forsman, president of the Clinical Laboratory Management Association. “It becomes a consumable like Starbucks or bottled water.”

    My advice? I strongly recommend that someone from ANY LAB TEST NOW contact the guys running GNC and explore co-franchising options.

    They completely deserve each other.

    January 18th, 2012

    ID Case Conference Discussant Types

    We specialists in Infectious Diseases love case conferences — especially those where the case is presented as an “unknown”, and we try to figure out the diagnosis from the history.

    I suppose this isn’t very surprising, since ID cases in general are already among the most interesting in all of medicine. Those that are case-conference-worthy are particularly prime.

    “Funny bug in a funny place,” was how one of my colleagues characterized these cases.

    After the case is presented, the discussion by the participants takes various forms. I’ve been to hundreds of these conferences over the years, and have noted that the path taken by the discussants to arrive at the diagnosis (or not) varies quite a bit. There are certain styles, certain patterns of medical thinking in the conference room (rather than in the exam room or at the bedside) that show up again and again:

    • The instinctual, “Here’s the diagnosis” approach. Very valuable when spoken by the Giants in the Field, who usually have several decades of clinical experience. These are short, targeted discussions that impressively even list the possible diagnoses in order of likelihood. Lou Weinstein was the quintessential “here’s the diagnosis” guy; sadly I only got to hear him discuss cases in the last few years of his distinguished career. Not surprisingly, this kind of medical reasoning doesn’t work nearly as well when attempted by relative beginners, e.g., a medical student, or even a second-year ID fellow. Bottom line: Beware the clinician in his/her 20s who begins a case discussion with the phrase, “In my clinical experience …”
    • The comprehensive, “I’ve considered the entire universe of living organisms” approach. Can be both spectacularly interesting and educational or, conversely, crushingly, mind-numbingly boring. Mort Swartz (another Giant in the Field) discusses cases in this style, and I learn something from Mort every time — his knowledge not only of ID but all of Internal Medicine is awe-inspiring. However, my heart always sinks when a mere non-Mort mortal (couldn’t resist) starts a discussion by listing all the main categories of microorganisms as a prelude:  “Let’s see, as potential causes for this person’s infected hip, there are prions, viruses, aerobic and anaerobic bacteria, higher bacteria, mycobacteria, fungi, algae, protozoa, helminths, ectoparasites …” Time to get some more coffee.
    • The prodding, “Let’s stop this game and tell me the diagnosis” approach. Usually goes something like this: A generic case is presented with minimal information — let’s say a man with a skin infection. No further history is given. And the discussant, not surprisingly, prods the presenter to give more information. “Any cats?” he/she asks, thinking Pasturella multocida or bartonella. “Any water exposure?” thinking Aeromonas hydrophila or Vibrio vulnificus. Because the discussant knows a simple skin infection is never going to make it to case conference, he/she keeps searching — there MUST be something interesting about the epidemiology. The presenter relents: “Well, as it turns out, the patient works as a clam shucker.” Bingo, Mycobacterium marinum or Erysipelothrix rhusiopathiae.
    • The diverting “I don’t know what this diagnosis is, but I certainly know a lot about other stuff, so let’s talk about that” approach. This clever strategy usually involves a true expert in a field forced out of his or her comfort zone. The world expert on salmonella, for example, suddenly finds him/herself discussing a hospital-acquired pneumonia in a patient who’s just had cardiac surgery. You can be sure that eventually the subject of intracellular pathogens (of which salmonella is an excellent example) will come up — somehow.
    • The deer in a headlights, “You talking to me?” approach. Happens frequently when someone gets called on to discuss a case who’s not expecting it. Perhaps they’re junior faculty. Or just shy. Or maybe their mind has wandered, and they’re thinking about the Patriots’ playoff game, or whether to have another muffin, or the Krebs cycle. (I have never spontaneously thought about the Krebs cycle — see Figure above for a refresher.) And I’ve been informed by one of my most esteemed colleagues that some people just hate being called on, which I totally respect. (But others love yacking away during conference — they get offended if they’re not asked to opine — so it would be helpful to know how people feel about this. A green sticker on your white coat, perhaps, one that reads, “CALL ON ME!”) Suffice to say the startled discussant rarely gets the diagnosis correct, but they are often inadvertently funny.

    Here’s a tip — if you’re ever asked about a case during conference, and you haven’t been listening, and the person being discussed is acutely ill, just say, “It could be staph.” If chronically ill, “It could be TB.” You will never be wrong.

    What kind of discussant are you?

    January 10th, 2012

    First Rabies Case in State in Over 75 Years Raises Questions (Again) About Preventive Strategies

    The recent case of bat-related rabies in a Barnstable man has prompted my colleague Larry Madoff, director of the Division of Epidemiology and Immunization at the Mass Department of Public Health, to write this fine commentary in the Atlantic.

    I particularly like these passages:

    Rabies is perhaps the archetypal zoonotic disease, one spread between animals and humans. It has an extremely broad host range, with the ability to infect all mammals. The ancients understood that when a mad dog bit another dog, it too became mad … While rabies is transmissible between any species, most transmission occurs within the species — bat to bat, raccoon to raccoon — and the virus adapts slightly to its host. That means each virus carries a signature in its genetic sequence indicating the species and geographic location of the “donor.”

    He also states, “Keeping bats out of our homes, particularly our sleeping quarters, is a key public health measure in reducing human rabies.”

    But as I’ve written before, I’m not so sure the numbers back this up as an effective preventive measure — or at least one we can quantify. Sure, we should try to keep bats out of our bedrooms, and I’d be quick to get immunized if one bit me.

    But will these individual efforts — or the recommended practice of giving rabies immune globulin plus the vaccine series for “bats in the bedroom” exposures — actually reduce the number of rabies cases? Maybe not.

    To recap the logic in this Canadian study:

    • Bats in houses — incredibly common.
    • People seeking preventive immunization with bats in the house — very rare (though some summer evenings I bet emergency room docs feel otherwise).
    • Cases of bat-related rabies — EXTRAORDINARILY rare, often zero cases in a calendar year. The man from Barnstable was the fourth case in 2011 in the entire United States, the first rabies case in Massachusetts since 1935 — and first-ever bat-related case in the State.

    Since most people with bats in the house aren’t seeking immunization, and since the “number needed to treat” to prevent a single case of rabies is estimated to be 2.7 million (!), the Canadians scrapped the recommendation that people who awaken to find a bat flying around their room get immunized.

    And according to Larry, the World Health Organization now advocates a middle ground strategy of vaccine alone for minimal risk exposures. (US guidelines recommend rabies immune globulin as well.)

    Time will tell whether these less aggressive approaches to rabies prevention will be the right move.

    But I have a sneaking suspicion that sporadic cases will continue to occur — fortunately rarely — no matter what we do.

    January 8th, 2012

    Journal Club: In Early HIV Infection, Little Reason to Delay Therapy

    Every experienced HIV clinician will recognize the following new-patient scenario:

    • At least one, but often several negative HIV antibody tests in the past, generally due to being in a “high risk” group.
    • Recent non-specific viral-type illness that, in hindsight, was undoubtedly acute HIV infection, undiagnosed.
    • Now completely recovered, but found to be newly HIV antibody positive.
    • Physical exam normal, CD4 500 or higher, HIV RNA in the moderate range (10-100K).

    How should patients like these be managed? Specifically, should antiretroviral therapy be started, or should they be observed?

    Over in Journal of Infectious Diseases, the so-called Setpoint study — a randomized strategy trial — investigated whether a 36-week period of treatment would delay the need to go on continuous HIV therapy, compared with observation. After 130 of a planned 150 patients were enrolled, a Data Safety Monitoring Board elected to stop the study due to this key finding:  “… the higher rate of progression to needing treatment in the Deferred Treatment group (50%) versus the Immediate Treatment (10%) group.”

    Importantly, the findings would have been even stronger in favor of Immediate Treatment if more up-to-date CD4 thresholds (500 rather than 350) were used as a criterion to start therapy. (The study was designed in the mid 2000s.)

    How do these results influence practice? As I’ve noted before, patients diagnosed with recently-acquired HIV infection should be counseled that even if treatment is deferred, there is a high likelihood they will need to start treatment relatively soon.

    It’s also time to retire the “you may have 10 years before needing to go on therapy” counseling, something we might have been prone to do in the past to soften the blow of someone hearing that they’re HIV positive. This kind of delay is highly unlikely, and may be limited to the small fraction of patients who have very low HIV RNA and very high CD4s.

    January 4th, 2012

    How Does Herpes Treatment Trigger a Positive Test for Performance-Enhancing Drugs?

    Here’s my guess on how many of this blog’s readers know the following “facts”:

    • Acyclovir and related drugs are used to treat herpes: nearly 100%
    • Ryan Braun, superstar left fielder for the Milwaukee Brewers, is facing a 50 game suspension for testing positive for elevated levels of a “banned substance”, most likely testosterone: 10%
    • Braun has disputed the results, stating that it’s a false-positive caused by treatment he’s receiving for a “private medical issue”: 1%
    • That medical issue is widely rumored to be herpes: 0.01%

    Now I should mention that I am a huge Ryan Braun fan, not only because of his stellar play, and his nickname (“The Hebrew Hammer”, one Braun shares with Hammerin’ Hank Greenberg), but also because he bears an uncanny resemblance to my nephew.

    But it’s that last bullet point I can’t quite figure out — treatment of herpes is incredibly safe. How in the world would it lead to an elevated level of testosterone?

    Turns out, it doesn’t.

    But a quick search of “acyclovir” and “testosterone”, plus a perusal of an actual book — the irreplacable The Use of Antibiotics — finds that there are some obscure animal studies suggesting that anti-herpes drugs could do the reverse, i.e., lower testosterone levels.

    From the book:

    Dose-related testicular atrophy and abnormalities of spermatogenesis were noted in mice, rats and dogs treated on repeated occasions with either famciclovir or penciclovir …

    All of which leads me to the very speculative conclusion that some doctors could be providing testosterone supplementation to their patients receiving anti-herpes therapy.

    Which is, frankly, a completely bogus indication, way more “out there” as a practice than the typical off-label use of approved medications.

    But that’s the only way I can connect the dots here.

    In other words, something’s not right — the test result, the diagnosis, the prescribing practice — we just don’t know what that is yet.

    HIV Information: Author Paul Sax, M.D.

    Paul E. Sax, MD

    Contributing Editor

    NEJM Journal Watch
    Infectious Diseases

    Biography | Disclosures | Summaries

    Learn more about HIV and ID Observations.